Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri Approved In EU; Biogen Will Initiate A Staggered Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen Idec/Elan’s natalizumab is indicated for second-line use, mirroring the revised U.S. indication.

You may also be interested in...



Biogen Idec Shifts Gears On Tysabri Relaunch

“Phase II” will focus on efficacy and broadening use of the multiple sclerosis therapy, CEO Mullen tells investors.

Biogen Idec Shifts Gears On Tysabri Relaunch

“Phase II” will focus on efficacy and broadening use of the multiple sclerosis therapy, CEO Mullen tells investors.

1,000 Physicians, 4,500 Patients Enrolled In Tysabri TOUCH Program

Elan reports early data on uptake of the MS therapy, but says it is too early to tell how many enrollees will convert to patients treated.

Related Content

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel